Amarin Wins Off-Label Battle with US FDA
This article was originally published in SRA
Executive Summary
US drug makers everywhere owe Amarin Pharmaceuticals a big pat on the back for challenging the US Food and Drug Administration's threats of bringing misbranding actions against manufacturers that seek to promote their drugs for off-label uses1,2, said Philadelphia lawyer James Beck, counsel in the life sciences industry group at Reed Smith.